Literature DB >> 16041244

Dopamine transporter (SLC6A3) 5' region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease.

Samir N Kelada1, Paola Costa-Mallen, Harvey Checkoway, Christopher S Carlson, Terri-Smith Weller, Phillip D Swanson, Gary M Franklin, W T Longstreth, Zahra Afsharinejad, Lucio G Costa.   

Abstract

The dopamine transporter (DAT) plays a critical role in dopaminergic neurotransmission and is also the major site of action for some drugs of abuse. The coding region of the DAT gene, SLC6A3, is well conserved, but non-coding regions are more variable, most notably a variable number of tandem repeats (VNTR) polymorphism in the 3' untranslated region, which has been studied in a number of dopamine-related neurological disorders, including Parkinson's disease (PD). We aimed to characterize variation in the 5' region of SLC6A3 because little is known about the extent of variation in this region and potential consequences of such variation on gene expression. We identified multiple single nucleotide polymorphisms (SNPs) covering approximately 5000 bp 5' of exon 1 through the start of exon 2 (+2106). These SNPs segregated as eight haplotypes, six of which were common. These haplotypes differed significantly in activity in a reporter gene activity assay. However, we did not observe associations between common SNPs or haplotypes and PD in a case-control study of 261 incident cases and 376 age- and gender-matched unrelated controls. By contrast, we did observe a modest association of the 3' VNTR 9-repeat allele with PD (odds ratio=1.45; 95% confidence interval=1.04-2.03). This association was limited to subjects 60 years of age and greater versus those less than 60 years of age. We conclude that although DAT 5' region SNPs haplotypes significantly alter in vitro transcriptional activity, they are not related to PD risk. In addition, our findings provide further evidence supporting an association of PD with the VNTR polymorphism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041244     DOI: 10.1097/01.fpc.0000170917.04275.d6

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  20 in total

1.  Human dopamine transporter gene: differential regulation of 18-kb haplotypes.

Authors:  Ying Zhao; Nian Xiong; Yang Liu; Yanhong Zhou; Nuomin Li; Hong Qing; Zhicheng Lin
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

2.  Comparative analyses of human single- and multilocus tandem repeats.

Authors:  Darren Ames; Nick Murphy; Tim Helentjaris; Nina Sun; Vicki Chandler
Journal:  Genetics       Date:  2008-06-18       Impact factor: 4.562

3.  Potential for diagnosis versus therapy monitoring of attention deficit hyperactivity disorder: a new epigenetic biomarker interacting with both genotype and auto-immunity.

Authors:  Walter Adriani; Emilia Romano; Mariangela Pucci; Esterina Pascale; Luca Cerniglia; Silvia Cimino; Renata Tambelli; Paolo Curatolo; Oleg Granstrem; Mauro Maccarrone; Giovanni Laviola; Claudio D'Addario
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-08-18       Impact factor: 4.785

Review 4.  Of Pesticides and Men: a California Story of Genes and Environment in Parkinson's Disease.

Authors:  Beate R Ritz; Kimberly C Paul; Jeff M Bronstein
Journal:  Curr Environ Health Rep       Date:  2016-03

5.  SLC6A3 is a risk factor for Parkinson's disease: a meta-analysis of sixteen years' studies.

Authors:  Desheng Zhai; Songji Li; Ying Zhao; Zhicheng Lin
Journal:  Neurosci Lett       Date:  2013-11-07       Impact factor: 3.046

6.  Dopamine transporter genetic variants and pesticides in Parkinson's disease.

Authors:  Beate R Ritz; Angelika D Manthripragada; Sadie Costello; Sarah J Lincoln; Matthew J Farrer; Myles Cockburn; Jeff Bronstein
Journal:  Environ Health Perspect       Date:  2009-02-22       Impact factor: 9.031

7.  Functional analysis of upstream common polymorphisms of the dopamine transporter gene.

Authors:  Mikhil N Bamne; Michael E Talkowski; Kodavali V Chowdari; Vishwajit L Nimgaonkar
Journal:  Schizophr Bull       Date:  2009-03-09       Impact factor: 9.306

Review 8.  Molecular genetics of monoamine transporters: relevance to brain disorders.

Authors:  K Haddley; A S Vasiliou; F R Ali; U M Paredes; V J Bubb; J P Quinn
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

9.  Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.

Authors:  Sean P David; Richard A Brown; George D Papandonatos; Christopher W Kahler; Elizabeth E Lloyd-Richardson; Marcus R Munafò; Peter G Shields; Caryn Lerman; David Strong; Jeanne McCaffery; Raymond Niaura
Journal:  Nicotine Tob Res       Date:  2007-08       Impact factor: 4.244

10.  Pesticides that inhibit the ubiquitin-proteasome system: effect measure modification by genetic variation in SKP1 in Parkinson׳s disease.

Authors:  Shannon L Rhodes; Arthur G Fitzmaurice; Myles Cockburn; Jeff M Bronstein; Janet S Sinsheimer; Beate Ritz
Journal:  Environ Res       Date:  2013-08-27       Impact factor: 6.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.